April MIMS update

We look at some of the recent changes to the medicines landscape, with new products as well as changes to indications New products Belzutifan (Welireg) is an inhibitor of hypoxia‑inducible factor 2 alpha (HIF‑2α). HIF‑2α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Total uncertainty’ reigns over aged care pharmacist funding
Next Stewardship praised